Trial Profile
A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-15 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Malignant melanoma
- Focus Adverse reactions
- 06 May 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 13 Jun 2011 New trial record